Verona Pharma plc : PDMR Dealing
Updated : 13:57
LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on November 29, 2017, Dr. David Ebsworth, Non-Executive Chairman of the Company, purchased 10,000 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 106.85 pence per Ordinary Share. Following the acquisition, Dr. Ebsworth will have an interest in the Company of 135,787 Ordinary Shares, representing 0.13% of the Company's issued share capital.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
| a) | Name | David Ebsworth | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Non-Executive Chairman | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Verona Pharma plc | ||
| b) | LEI | 213800EVI6O6J3TIAL06 | ||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of 5 pence each | ||
| Identification code | GB00BYW2KH80 | |||
| b) | Nature of the transaction | David Ebsworth purchased 10,000 Ordinary Shares | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| 106.85 pence per Ordinary Share | 10,000 Ordinary Shares | |||
| d) | Aggregated information | N/A | ||
| - Aggregated volume | ||||
| - Price | ||||
| e) | Date of the transaction | 29 November 2017 | ||
| f) | Place of the transaction | London Stock Exchange, AIM | ||
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive Officer | info@veronapharma.com |
| Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) | Tel: +44 (0) 20 7710 7600 SNELVeronaPharma@stifel.com |
| Stewart Wallace / Jonathan Senior / Ben Maddison |
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Verona Pharma plc via Globenewswire